Case Report

A 55-year-old man presented with acute onset of a constant, generalised, severe headache. He described a two-day history of intermittent fevers but had no other infective symptoms. He had no visual symptoms. The patient had a history of T-cell prolymphocytic leukaemia for which he was undergoing chemotherapy with deoxycoformycin (7.2 mg–4 mg/m²) and alemtuzumab (30 mg three times a week). He was not known to be hypertensive and had not had any previous seizures. He had no other significant medical history.

His condition deteriorated over the next few hours. He became more agitated and confused and developed grand mal seizures. The patient was treated with intravenous (IV) benzodiazepines but developed status epilepticus and required intubation and ventilation. He was commenced on IV phenytoin.

Figure 1 shows the patient’s blood pressure and pulse rate, via intra-arterial monitoring, during his time in critical care. He had episodes of low-grade fever (37.4°C). His initial blood results showed a pancytopenia (white cell count [WCC] 1.0 x 10⁹/l, haemoglobin 9.5 g/dl, platelet count 78 x 10⁹/l with normal urea and electrolytes [creatinine 67 µmol/l]) and an international normalised ratio of 1.4. His initial arterial blood gas on 60% oxygen, post-seizure, showed a respiratory acidosis with a pH of 7.24, partial pressure of oxygen of 18.9 kPa, partial pressure of carbon dioxide of 9.4 kPa, bicarbonate ion of 28.4 mmol/l and base excess of –0.4 mEq/l. His electrocardiogram showed a sinus tachycardia with no other abnormalities.

Initial computerised tomography (CT) of the patient’s brain showed white matter oedema in both occipital lobes with no evidence of raised intra-cranial pressure. Cerebrospinal fluid (CSF) was clear and colourless in appearance with normal results (WCC <3 x 10⁹/l, red cell count 10 x 10⁹/l, glucose 3.6 mmol/l and protein 0.36 g/l). Gram stain was negative and subsequent CSF testing for cytomegalovirus, Epstein-Barr virus, enterovirus, JC virus, BK virus, meningococcus and toxoplasma were all negative. The patient did not receive an electroencephalograph as there is not an inpatient neurophysiology service at our hospital (a specialist tertiary oncology centre).
He underwent a magnetic resonance image scan (MRI) of his brain (T1- and T2-weighted images with contrast), which showed bilateral symmetrical white matter oedema in the parieto-occipital lobes on T2-weighted images (Figure 2). There was sparing of the medial occipital cortex and calcarine. There was no enhancement on T1-weighted images. Thus, a diagnosis of posterior reversible encephalopathy syndrome (PRES) was made.

The patient was transferred to intensive care where he remained intubated and ventilated for 24 hours. He was empirically treated with IV antimicrobial agents (meropenem, linezolid, voriconazole and ganciclovir). He received supportive treatment with IV metoprolol to maintain tight blood pressure control and IV phenytoin infusion.

He had periods of agitation post extubation requiring intermittent doses of sedative agents. He had no further seizures and made steady progress to discharge from hospital, with his symptoms resolving within two weeks. Anti-convulsant therapy was required for the acute management of PRES, but long-term treatment is not necessary.

Although, as the name implies, PRES is typically reversible, some lesions may produce irreversible damage. The features are typically reversed within two weeks of the onset of symptoms. Haemorrhage is a potential complication, particularly in patients with a coagulopathy (especially those with a platelet count less than 80 x 10^9/l) and those treated with immunosuppressive agents.

The key goal of management is controlling blood pressure and stopping any trigger agents. Given the wide range of conditions associated with PRES and the variation in signs and symptoms described in the syndrome, an awareness of the condition among all physicians is important. Early treatment of blood pressure has been associated with improved outcomes in PRES. Anticonvulsant therapy is required for the acute management of PRES, but long-term treatment is not necessary.

Posterior reversible encephalopathy syndrome is a rare but probably under-recognised syndrome. Consideration of the diagnosis, particularly in those receiving chemotherapeutic agents, is important as early treatment has been associated with improved outcomes.

Acknowledgements We would like to thank Dr Bloor, Consultant Haematologist, and his team and the Critical Care staff at the Christie for their support in the management of this patient.
REFERENCES


INVITATION TO SUBMIT PAPERS

We would like to extend an invitation to all readers of The Journal of the Royal College of Physicians of Edinburgh to contribute original material, especially to the clinical section. The JRCPE is a peer-reviewed journal with a circulation of 8,000. Its aim is to publish a range of clinical, educational and historical material of cross-specialty interest to the College’s international membership.

The JRCPE is currently indexed in Medline, Embase, Google Scholar and the Directory of Open Access Journals. The editorial team is keen to continue to improve both the quality of content and its relevance to clinical practice for Fellows and Members. All papers are subject to peer review and our turnaround time for a decision averages only eight weeks.

We would be pleased to consider submissions based on original clinical research, including pilot studies. The JRCPE is a particularly good forum for research performed by junior doctors under consultant supervision. We would also consider clinical audits where the ‘loop has been closed’ and a demonstrable clinical benefit has resulted.

For further information about submissions, please visit: http://www.rcpe.ac.uk/journal/contributers.php or e-mail editorial@rcpe.ac.uk. Thank you for your interest in the College’s journal.

The editorial team,
The Journal of the Royal College of Physicians of Edinburgh